Press release Leuven / 3 August 2021



QUEST FOR GROWTH

Privak/pricaf, public alternative investment fund (AIF) with fixed capital under Belgian law

Acquisition of HalioDx closed

Veracyte Inc. has announced that the transaction to acquire HalioDx SAS, which was referred to in the press release of Quest for Growth of 1 June 2021, was successfully closed. HalioDx is a private immuno-oncology diagnostic company based in Marseille, France. Quest for Growth has invested in the company in 2017.

The closing of the transaction has an additional positive impact on the net asset value of Quest for Growth of approximately \in 1.8 million or \in 0.11 per share, which will be included in the net asset value calculation of the end of August, to be published on 2 September 2021. The total positive impact of the sale of HalioDX on the net asset value evolution of Quest for Growth in 2021 is estimated at approximately \in 7.5 million or \in 0.45 per share.

About Quest for Growth

QUEST FOR GROWTH is a privak/pricaf, a public alternative investment fund (AIF) with fixed capital under Belgian law, managed by Capricorn Partners NV. The diversified portfolio of Quest for Growth is for the most part invested in growth companies listed on European stock exchanges, in European unquoted companies and in venture capital funds. Quest for Growth focuses on innovative companies in areas such as digital technologies (ICT), technologies for the healthcare sector (Health-tech) and clean technology (Cleantech). Quest for Growth has been listed on Euronext Brussels since 23 September 1998.

For further information: Yves Vaneerdewegh,

member of the executive committee of Capricorn Partners NV

tel +32 (0)16 28 41 00

